KA
IMGN

Kercheville Advisors’s Immunogen Inc IMGN Stock Holding History

Kercheville Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-114,897
Closed -$3.41M – 95
2023
Q4 		$3.41M Sell
114,897
-1,680
-1% -$33.5K 1.91% 19
2023
Q3 		$1.85M Sell
116,577
-59,463
-34% -$989K 1.17% 27
2023
Q2 		$3.32M Sell
176,040
-76,512
-30% -$903K 2.01% 20
2023
Q1 		$970K Sell
252,552
-26,075
-9% -$111K 0.66% 33
2022
Q4 		$1.38M Buy
278,627
+40,325
+17% +$219K 0.95% 28
2022
Q3 		$1.14M Buy
238,302
+1,100
+0.5% +$5.8K 1.16% 24
2022
Q2 		$1.07M Buy
237,202
+10,600
+5% +$46.1K 0.7% 32
2022
Q1 		$1.08M Buy
226,602
+19,950
+10% +$110K 0.51% 42
2021
Q4 		$1.53M Buy
206,652
+16,950
+9% +$105K 0.67% 34
2021
Q3 		$1.08M Sell
189,702
-7,300
-4% -$42.2K 0.51% 45
2021
Q2 		$1.3M Buy
197,002
+3,247
+2% +$22.7K 0.6% 47
2021
Q1 		$1.56M Sell
193,755
-50,666
-21% -$414K 0.78% 38
2020
Q4 		$1.56M Buy
+244,421
New +$1.43M 0.85% 33

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kercheville Advisors's IMGN Position: Q1 2024 in Review

Kercheville Advisors sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 114,897 shares — an estimated $3.41M sold.

Kercheville Advisors first reported a position in IMGN in Q4 2020 and held it in 13 quarters. The position peaked at $3.41M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Kercheville Advisors reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Kercheville Advisors sold 114,897 Immunogen Inc shares in Q1 2024, an estimated $3.41M.
  • Kercheville Advisors first reported a position in Immunogen Inc in Q4 2020 and held it in 13 quarters.
  • Kercheville Advisors's Immunogen Inc position peaked at $3.41M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Kercheville Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.